The effect of laparoscopic gastric bypass on dyslipidemia in severely obese patients: a 5-year follow-up analysis.
Dyslipidemia is common in the morbidly obese population. A previous study from our institution demonstrated improved lipid parameters 1 and 2 years after laparoscopic Roux-en-Y gastric bypass (LRYGB) with fewer patients taking lipid-modifying medications postoperatively, suggesting cost-savings over time. Our objective was to evaluate lipid parameters and lipid-modifying medication use at 5 years postoperative. The medical records of patients who underwent LRYGB from September 2001 through July 2008 were reviewed. Inclusion criteria consisted of both preoperative and 5-year postoperative lipid values available. Six hundred eighty-two patients underwent LRYGB during the study period; 450 had data available at 5 years postoperative, and 187 patients met the inclusion criteria. Mean age was 46.3 years, and 83 % were women. Mean preoperative body mass index was 47.4 kg/m(2). Total cholesterol was 191.2 ± 35.4 preoperatively and 181.1 ± 33.0 at 5 years postoperative (P = 0.003). Low-density lipoprotein (LDL) was 107.9 ± 30.9 preoperatively and 95.3 ± 29.7 at 5 years postoperative (P < 0.001). High-density lipoprotein (HDL) was 48.7 ± 12.8 preoperatively and 65.1 ± 18.0 at 5 years postoperative (P < 0.001). Triglycerides were 171.3 ± 78.6 preoperatively and 112.9 ± 60.7 5 years postoperative (P < 0.001). Preoperatively, 35 % of patients were on lipid-modifying medications, and at 5 years postoperatively, 26 % required lipid-modifying medications (P = 0.002). Patients who have undergone LRYGB continue to show favorable change in their lipid profiles at 5 years postoperative. Furthermore, fewer patients were taking lipid-modifying medications at 5 years postoperatively than preoperatively.